Turin, Italy – 29 September 2026
Read MorePress releases
Kither Biotech and Pantherna Therapeutics Announce Strategic Collaboration on Synergistic mRNA and Peptide Therapies for Genetic Lung Diseases
Turin (Italy) / Hennigsdorf (Germany), 08.01.2026
Read MoreKither Biotech Announces Phase 1 Clinical Study Of KIT2014, A Novel Inhaled Peptide Therapy For Cystic Fibrosis
Turin, Italy – October 30, 2024 – Kither Biotech, a clinical-stage biotech company focused on innovative therapies for respiratory diseases,…
Read MoreKither Biotech Announces Appointment of Dr. Dimitrios Goundis to Board of Directors
Turin, Italy, 13 November 2023 – Kither Biotech (“Kither” or “the Company”), a pioneering biopharmaceutical firm committed to developing novel…
Read MoreKither Biotech announces publication of new data in Science Translational Medicine
Turin, Italy, 31 March 2022 – Data support the use of Kither Biotech’s lead asset, KIT2014, in obstructive airway diseases…
Read MoreKither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
Turin, Italy, 16 March 2022 – Kither Biotech (“Kither” or “the Company”), a biopharmaceutical company developing novel therapies for rare…
Read MoreKither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases
Turin, Italy, 5 July 2019 – Kither Biotech raises a €5.6m financing round to support the clinical development of a…
Read More